Physician profile
Jason A Ham
NPI 1245560796
$5,789.77
in general payments reported to CMS, 2019-2025
45 companies · $854 in 2025
The $854 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $735 · 2020: $1,028 · 2021: $1,232 · 2022: $674 · 2023: $615 · 2024: $651 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,120.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $671.87 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $494.66 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $455.23 | 2020-2024 | |
| Pfizer INC. | $404.15 | 2019-2025 | |
| Novo Nordisk INC | $365.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $361.76 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.29 | 2020-2025 | Tradjenta, Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $224.96 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.61 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $176.78 | 2019-2021 | |
| Astellas Pharma US INC | $160.95 | 2020-2024 | Veozah |
| Merck Sharp & Dohme LLC | $156.82 | 2019-2024 | Capvaxive, M-M-R II, Gardasil |
| Allergan, INC. | $156.76 | 2019-2020 | |
| Antares Pharma, INC. | $149.28 | 2022 | |
| Axsome Therapeutics, INC. | $144.52 | 2023-2025 | Auvelity, Sunosi |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Ham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.